Halovir

Halovir refers to a multi-analogue compound belonging to a group of oligopeptides designated as lipopeptaibols (chemical features including lipophilic acyl chain at the N-terminus, abundant α-aminoisobutyric acid content, and a 1,2-amino alcohol located at the C-terminus) which have membrane-modifying capacity and are fungal in origin. These peptides display interesting microheterogeneity; slight variation in encoding amino acids gives rise to a mixture of closely related analogues and have been shown to have antibacterial/antiviral properties.

Background

Nonribosomal peptides compose a significant group of secondary metabolites in bacterial/fungal organisms (though Drosophila melanogaster and Caenorhabditis elegans both exhibit products of nonribosomal peptide synthetases); having been observed functioning as self-defense substances/iron-chelating siderophores, they serve as coping mechanisms for environmental stress, perform as virulence factors/toxins promoting pathogenesis, and act in signalling (enabling communications within and between species). In lieu of these functionalities, many nonribosomal peptides have been utilized in development of medical drugs and biocontrol agents (examples of such include β-lactams, daptomycin, echinocandins, emodepside, bleomycin, cyclosporine, and bialaphos).

Peptaibols are a family of linear, amphipathic polypeptides (typically consisting of 4-21 amino acids residues) that are generated as a result of the assembly of a variety of aminoacyl, ketoacyl or hydroxyacyl monomers by fungal multimodular megaenzymes denoted as nonribosomal-peptide synthetases (NRPSs). Typically, NRPSs are composed of three highly conserved core domains: an adenylation (A) domain which recognizes, activates and loads monomers onto NRPS, a thiolation (T) domain (also denoted as the peptidyl carrier protein domain) that transports covalently linked monomers/peptidyl intermediates between nearby NRPS domains, and a condensation (C) domain (catalyzes sequential condensation of monomers within the nascent peptide chain). In addition, a chain-terminating domain [thioesterase (TE) domain, a terminal C (CT) or a reductase (R) domain] is commonly observed at the end of an NRPS in order to relinquish full-length peptide chains in linear or cyclic forms. Furthermore, often seen are feature tailoring domains [epimerase, N-methyltransferase (M), oxidase (Ox), ketoacyl reductase (KR) and cyclase (Cy)], allowing for further modification of monomers/polypeptide intermediates.

Notable characteristics of peptaibols include: C-terminal alcohol residues (phenylalaninol, leucinol, isoleucinol, valinol), an N-acyl terminus (usually acetyl), and high levels of α,α-dialkylated non-proteinogenic amino acids [α-aminoisobutyric acid (Aib), isovaleric acid (Iva), hydroxyproline (Hyp)]. In most cases, peptaibols form α-helix and β-bend patterns in their 3D structures (α-aminoisobutyric acid is a turn/helix forming agent). α,α-dialkylated amino acid residues in peptaibols create substantial conformation constrictions in the peptide backbone, resulting in the formation of right-handed α-helical structures. Membrane modification abilities can be attributed to the formation of transmembrane voltage-dependent channels; this occurs as the peptide takes on an α-helical conformation upon contact of lipid bilayers, drilling through and forming ion channels with similar electrophysiological configurations of ion channel proteins. The principle functionality of the peptides is to rupture membranes, in turn triggering cytolysis via loss of osmotic balance.

Structurally speaking, lipopeptaibols are peptaibols with a fatty acyl moiety linked to the N-terminal amino acid (thusly named), and have been isolated from a number of soil fungi. Their primary structures all have the L-(S-) configuration at the 2-(α-)carbon. They overwhelmingly display microheterogeneity (being very structurally similar; with a limited pool of conserved variation in natural sample).

Structure

Approximate modeling of Halovir A peptide sequence (without myristoyl tail) using PyMOL 2.5

-Halovir A: contains L-leucine, L-valine, and L-glutamine

-Halovir B: contains L-alanine, L-leucine, L-glutamine

-Halovir C: contains L-leucine, L-valine, L-glutamine,

-Halovir D

-Halovir E

-Halovir I

-Halovir J

-Halovir K

Medical applications

The antibiotic capabilities of these compounds can be attributed to membrane insertion and pore-forming functionalities, and typically exhibit antimicrobial activity in Gram-positive bacteria and fungi.

Halovirs A-E (isolated from Scytidium sp.) has displayed potent antiviral activity against HSV-1, and has been observed performing replication inhibition of HSV-1 and HSV-2 in standard plaque reduction assay without cytotoxicity (at concentrations upwards of 0.85μM) Mechanistic studies suggest that halovirs kills virus in direct contact and in a time-dependent manner before it can affect host cells.

Halovirs I and J were analyzed for antibacterial and cytotoxic activities, and displayed significant growth inhibition against two Gram-positive bacteria (Staphylococcus aureus and Enterococcus faecium), but not Gram-negative Escherichia coli. Notably, these two halovirs were found to be effective against methicillin-resistant S. aureus (MRSA) and vancomycin-resistant E. faeccium, indicating that the activity against them to be persistent. Additionally, strong cytotoxic activity was observed against a panel of cancer cell lines, including: human lung carinoma A549, human breast carcinoma MCF-7, and human cervical carcinoma HeLa cells (cytotoxicity was not specific to cancer cells in the referenced study).

References

  1. 1 2 "Halovir, an antiviral marine natural product, and derivatives thereof - Patent US-2003013659-A1 - PubChem". pubchem.ncbi.nlm.nih.gov. Retrieved 2022-10-09.
  2. 1 2 3 4 Rowley, David C.; Kelly, Sara; Kauffman, Christopher A.; Jensen, Paul R.; Fenical, William (2004-02-10). "Halovirs A-E, New Antiviral Agents from a Marine-Derived Fungus of the Genus Scytalidium". ChemInform. 35 (6). doi:10.1002/chin.200406159. ISSN 0931-7597.
  3. ↑ Rowley, David C.; Kelly, Sara; Jensen, Paul; Fenical, William (September 2004). "Synthesis and structure–activity relationships of the halovirs, antiviral natural products from a marine-derived fungus". Bioorganic & Medicinal Chemistry. 12 (18): 4929–4936. doi:10.1016/j.bmc.2004.06.044. PMID 15336272.
  4. 1 2 3 4 Toniolo, C.; Crisma, M.; Formaggio, F.; Peggion, C.; Epand, R.F.; Epand, R.M. (August 2001). "Lipopeptaibols, a novel family of membrane active, antimicrobial peptides". Cellular and Molecular Life Sciences. 58 (9): 1179–1188. doi:10.1007/PL00000932. ISSN 1420-682X. PMC 11337402. PMID 11577977. S2CID 9679066.
  5. 1 2 Auvin-Guette, Catherine; Rebuffat, Sylvie; Prigent, Yann; Bodo, Bernard (March 1992). "Trichogin A IV, an 11-residue lipopeptaibol from Trichoderma longibrachiatum". Journal of the American Chemical Society. 114 (6): 2170–2174. doi:10.1021/ja00032a035. ISSN 0002-7863.
  6. 1 2 Xiao, Dongliang; Zhang, Mei; Wu, Ping; Li, Tianyi; Li, Wenhua; Zhang, Liwen; Yue, Qun; Chen, Xinqi; Wei, Xiaoyi; Xu, Yuquan; Wang, Chen (May 2022). "Halovirs I–K, antibacterial and cytotoxic lipopeptaibols from the plant pathogenic fungus Paramyrothecium roridum NRRL 2183". The Journal of Antibiotics. 75 (5): 247–257. doi:10.1038/s41429-022-00517-7. ISSN 0021-8820. PMID 35288678. S2CID 247451837.
  7. 1 2 3 4 5 6 7 8 9 10 Xiao, Dongliang; Zhang, Mei; Wu, Ping; Li, Tianyi; Li, Wenhua; Zhang, Liwen; Yue, Qun; Chen, Xinqi; Wei, Xiaoyi; Xu, Yuquan; Wang, Chen (May 2022). "Halovirs I–K, antibacterial and cytotoxic lipopeptaibols from the plant pathogenic fungus Paramyrothecium roridum NRRL 2183". The Journal of Antibiotics. 75 (5): 247–257. doi:10.1038/s41429-022-00517-7. ISSN 0021-8820. PMID 35288678. S2CID 247451837.
  8. 1 2 Richardt, Arnd; Kemme, Tobias; Wagner, Stefanie; Schwarzer, Dirk; Marahiel, Mohamed A.; Hovemann, Bernhard T. (2003-10-17). "Ebony, a novel nonribosomal peptide synthetase for beta-alanine conjugation with biogenic amines in Drosophila". The Journal of Biological Chemistry. 278 (42): 41160–41166. doi:10.1074/jbc.M304303200. ISSN 0021-9258. PMID 12900414.
  9. 1 2 Shou, Qingyao; Feng, Likui; Long, Yaoling; Han, Jungsoo; Nunnery, Joshawna K.; Powell, David H.; Butcher, Rebecca A. (October 2016). "A hybrid polyketide-nonribosomal peptide in nematodes that promotes larval survival". Nature Chemical Biology. 12 (10): 770–772. doi:10.1038/nchembio.2144. ISSN 1552-4469. PMC 5030153. PMID 27501395.
  10. 1 2 3 Süssmuth, Roderich; Müller, Jane; Döhren, Hans von; Molnár, István (2010-12-17). "Fungal cyclooligomer depsipeptides: From classical biochemistry to combinatorial biosynthesis". Natural Product Reports. 28 (1): 99–124. doi:10.1039/C001463J. ISSN 1460-4752. PMID 20959929.
  11. ↑ Felnagle, Elizabeth A.; Jackson, Emily E.; Chan, Yolande A.; Podevels, Angela M.; Berti, Andrew D.; McMahon, Matthew D.; Thomas, Michael G. (2008-04-01). "Nonribosomal Peptide Synthetases Involved in the Production of Medically Relevant Natural Products". Molecular Pharmaceutics. 5 (2): 191–211. doi:10.1021/mp700137g. ISSN 1543-8384. PMC 3131160. PMID 18217713.
  12. 1 2 Hou, Xuewen; Sun, Ruonan; Feng, Yanyan; Zhang, Runfang; Zhu, Tianjiao; Che, Qian; Zhang, Guojian; Li, Dehai (2022-09-01). "Peptaibols: Diversity, bioactivity, and biosynthesis". Engineering Microbiology. 2 (3) 100026. doi:10.1016/j.engmic.2022.100026. ISSN 2667-3703. PMC 11610996. S2CID 249417277.
  13. 1 2 Bills, Gerald; Li, Yan; Chen, Li; Yue, Qun; Niu, Xue-Mei; An, Zhiqiang (2014-09-11). "New insights into the echinocandins and other fungal non-ribosomal peptides and peptaibiotics". Natural Product Reports. 31 (10): 1348–1375. doi:10.1039/C4NP00046C. ISSN 1460-4752. PMID 25156669.
  14. 1 2 3 4 5 Wiest, Aric; Grzegorski, Darlene; Xu, Bi-Wen; Goulard, Christophe; Rebuffat, Sylvie; Ebbole, Daniel J.; Bodo, Bernard; Kenerley, Charles (2002-06-07). "Identification of Peptaibols from Trichoderma virens and Cloning of a Peptaibol Synthetase *". Journal of Biological Chemistry. 277 (23): 20862–20868. doi:10.1074/jbc.M201654200. ISSN 0021-9258. PMID 11909873.
  15. ↑ Whitmore, Lee; Wallace, B. A. (2004-01-01). "The Peptaibol Database: a database for sequences and structures of naturally occurring peptaibols". Nucleic Acids Research. 32 (Database issue): D593–D594. doi:10.1093/nar/gkh077. ISSN 0305-1048. PMC 308811. PMID 14681489.
  16. ↑ Marshall, G R; Hodgkin, E E; Langs, D A; Smith, G D; Zabrocki, J; Leplawy, M T (January 1, 1990). "Factors governing helical preference of peptides containing multiple alpha,alpha-dialkyl amino acids". Proceedings of the National Academy of Sciences of the United States of America. 87 (1): 487–491. Bibcode:1990PNAS...87..487M. doi:10.1073/pnas.87.1.487. ISSN 0027-8424. PMC 53289. PMID 2296604.
  17. ↑ Schweitzer-Stenner, Reinhard; Gonzales, Widalys; Bourne, Gregory T.; Feng, Jianwen A.; Marshall, Garland R. (2007-10-01). "Conformational Manifold of α-Aminoisobutyric Acid (Aib) Containing Alanine-Based Tripeptides in Aqueous Solution Explored by Vibrational Spectroscopy, Electronic Circular Dichroism Spectroscopy, and Molecular Dynamics Simulations". Journal of the American Chemical Society. 129 (43): 13095–13109. doi:10.1021/ja0738430. ISSN 0002-7863. PMID 17918837.
  18. ↑ Rebuffat, S.; Duclohier, H.; Auvin-Guette, C.; Molle, G.; Spach, G.; Bodo, B. (September 1992). "Membrane-modifying properties of the pore-forming peptaibols saturnisporin SA IV and harzianin HA V". FEMS Microbiology Immunology. 5 (1–3): 151–160. doi:10.1111/j.1574-6968.1992.tb05886.x. ISSN 0920-8534. PMID 1384595.
  19. 1 2 Sansom, Mark S. P.; Kerr, Ian D.; Mellor, Ian R. (1991-11-01). "Ion channels formed by amphipathic helical peptides". European Biophysics Journal. 20 (4): 229–240. doi:10.1007/BF00183460. ISSN 1432-1017. PMID 1725513. S2CID 23503646.
  20. 1 2 Huang, Huey W. (1996), "Structural Basis and Energetics of Peptide Membrane Interactions", in Merz, Kenneth M.; Roux, Benoît (eds.), Biological Membranes: A Molecular Perspective from Computation and Experiment, Boston, MA: Birkhäuser, pp. 281–298, doi:10.1007/978-1-4684-8580-6_9, ISBN 978-1-4684-8580-6
  21. ↑ "Support | pymol.org". pymol.org. Retrieved 2022-11-27.
  22. ↑ Jen, W. -C.; Jones, G. A.; Brewer, D.; Parkinson, V. O.; Taylor, A. (October 1987). "The antibacterial activity of alamethicins and zervamicins". Journal of Applied Bacteriology. 63 (4): 293–298. doi:10.1111/j.1365-2672.1987.tb02705.x. PMID 3436854.